Position in ABBV
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$4,171,184
+$248,752 QoQ
Shares Held
16,576
-8.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
5.21%
of 13F equity value
Holder Rank
#1,428
of 4,153 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Frazier Financial Advisors, LLC holds $5,122,500 across 11 Drug Manufacturers - General names. ABBV ranks #1 (81.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
This page
|
16,576 | $4,171,184 | |
| 2 | JNJ |
Johnson & Johnson
|
1,921 | $487,876 | |
| 3 | LLY |
ELI LILLY & Co
|
147 | $176,316 | |
| 4 | PFE |
Pfizer Inc
|
2,529 | $60,898 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
883 | $50,878 | |
| 6 | NVO |
Novo Nordisk A S
|
935 | $44,823 | |
| 7 | AMGN |
Amgen Inc
|
122 | $44,178 | |
| 8 | NVS |
Novartis AG
|
200 | $31,344 |
All Filings in ABBV
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,171,184 | 16,576 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $3,922,432 | 18,035 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $4,040,617 | 17,684 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $4,146,418 | 17,908 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $3,324,082 | 17,908 | Shares | Sole | 2025-07-28 | |
| 2025-03-31 | $3,768,217 | 17,985 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $3,267,014 | 18,385 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $3,383,819 | 17,135 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $2,933,849 | 17,105 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $3,098,795 | 17,017 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $2,798,913 | 18,061 | Shares | Sole | 2024-02-09 | |
| No filing history on record for this holder in this stock. | ||||||